 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
3 News |  |
- || lodapolimab (LY3300054) / Eli Lilly, LY3381916 / Eli Lilly
Clinical, P1 data, Journal, Combination therapy, Monotherapy: A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer. (Pubmed Central) - Mar 23, 2022
These preliminary data suggest an alternative dose level of LY3381916 is needed for the combination with PD-L1 inhibitor. The combination clinical activity was limited in this study.
- lodapolimab (LY3300054) / Eli Lilly, LY3381916 / Eli Lilly
Enrollment change, Trial termination, Combination therapy: A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (clinicaltrials.gov) - Jun 4, 2020
P1a/1b, N=60, Terminated, Sponsor: Eli Lilly and Company
The combination clinical activity was limited in this study. N=175 --> 60 | Active, not recruiting --> Terminated; Study terminated due to strategic business decision by Eli Lilly and Company.
- || lodapolimab (LY3300054) / Eli Lilly, LY3381916 / Eli Lilly
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (clinicaltrials.gov) - Feb 21, 2020
P1a/1b, N=175, Active, not recruiting, Sponsor: Eli Lilly and Company
N=175 --> 60 | Active, not recruiting --> Terminated; Study terminated due to strategic business decision by Eli Lilly and Company. Recruiting --> Active, not recruiting | Trial completion date: Feb 2022 --> May 2020 | Trial primary completion date: Jun 2021 --> Feb 2020
- LY3300054 / Eli Lilly, LY3381916 / Eli Lilly
A phase I study of an anti-IDO1 inhibitor (LY3381916) as monotherapy and in combination with an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer (Room B) - Oct 29, 2019 - Abstract #ESMOIO2019ESMO_IO_292;
P1a/1b
The 240mg dose QD is the RP2D for combination with PD-L1 in expansion cohorts.Legal entity responsible for the study: Eli Lilly and Company. Funding: Eli Lilly and Company.
- IDO1 inhibitor / Netherlands Translational Research Center (NTRC)
Side-by-side comparison of small molecule IDO1 inhibitors in biochemical and cell-based assays and development of a IDO1-expressing mouse model to evaluate target modulation (Board 60: Level 2 - Hall D) - Sep 18, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_289;
Treatment of the B16F10-IDO1 model with epacadostat did not result in a reduction of tumor growth, though epacadostat did induce clear changes in Trp and Kyn in both plasma and tumor tissue. Conclusion Our comparative study of the potencies and selectivities of IDO1 inhibitors, as well as our model for measuring in vivo target modulation, helps to identify strengths and weaknesses of current IDO1 inhibitors, and supports the development of new inhibitors.
- | lodapolimab (LY3300054) / Eli Lilly, LY3381916 / Eli Lilly
Enrollment change, Combination therapy: A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (clinicaltrials.gov) - Sep 11, 2019
P1a/1b, N=175, Recruiting, Sponsor: Eli Lilly and Company
Conclusion Our comparative study of the potencies and selectivities of IDO1 inhibitors, as well as our model for measuring in vivo target modulation, helps to identify strengths and weaknesses of current IDO1 inhibitors, and supports the development of new inhibitors. N=290 --> 175
- || lodapolimab (LY3300054) / Eli Lilly, LY3381916 / Eli Lilly
Trial initiation date, Combination therapy: A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (clinicaltrials.gov) - Apr 3, 2019
P1a/1b, N=290, Recruiting, Sponsor: Eli Lilly and Company
N=290 --> 175 Initiation date: Nov 2017 --> Feb 2018
- || lodapolimab (LY3300054) / Eli Lilly, LY3381916 / Eli Lilly
Trial completion date, Trial primary completion date, Combination therapy: A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (clinicaltrials.gov) - Mar 5, 2019
P1a/1b, N=290, Recruiting, Sponsor: Eli Lilly and Company
Initiation date: Nov 2017 --> Feb 2018 Trial completion date: Dec 2020 --> Feb 2022 | Trial primary completion date: Sep 2019 --> Jun 2021
- ||| lodapolimab (LY3300054) / Eli Lilly, LY3381916 / Eli Lilly
Enrollment open, Combination therapy: A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (clinicaltrials.gov) - Dec 4, 2017
P1a/1b, N=290, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Dec 2020 --> Feb 2022 | Trial primary completion date: Sep 2019 --> Jun 2021 Not yet recruiting --> Recruiting
- ||| lodapolimab (LY3300054) / Eli Lilly, LY3381916 / Eli Lilly
New P1 trial, Combination therapy: A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (clinicaltrials.gov) - Nov 17, 2017
P1a/1b, N=290, Not yet recruiting, Sponsor: Eli Lilly and Company